Related Experiment Videos
[Clinical study on cefixime granules in the field of pediatrics]
Insights
Cefixime (CFIX) granules showed high clinical effectiveness in pediatric tonsillitis and urinary tract infections, with a 94.4% success rate and no observed side effects. This new oral cephalosporin demonstrates promising results for pediatric infectious diseases.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
Context:
- Cefixime (CFIX) is a novel oral cephalosporin antibiotic.
- Pediatric tonsillitis and urinary tract infections (UTIs) are common conditions requiring effective treatment.
Purpose:
- To evaluate the absorption, excretion, and clinical effectiveness of cefixime granules in pediatric patients.
- To assess the pharmacokinetic profile and therapeutic outcomes of cefixime in children.
Summary:
- Cefixime demonstrated favorable absorption and excretion patterns in pediatric patients.
- Peak serum concentrations ranged from 0.545 to 1.56 micrograms/ml with half-lives averaging 3.29 hours.
- Clinical effectiveness was high, with an overall rate of 94.4% in treating tonsillitis and UTIs, and no significant side effects were reported.
Impact:
- Cefixime presents a safe and effective oral treatment option for pediatric tonsillitis and UTIs.
- The study supports the use of cefixime in pediatric populations based on its efficacy and safety profile.
Abstract:
The absorption and excretion and clinical effectiveness of cefixime (CFIX) granules, a new oral cephalosporin, were studied with pediatric patients with tonsillitis and urinary tract infection (UTI). Peak serum concentrations in 3 children given orally a single dose of 3 mg/kg on fasting were 0.545 micrograms/ml at 2 hours in 1 patient, and 1.56 and 1.26 micrograms/ml at 4 hours in the other 2. The half-lives in the 3 patients were 3.21-3.42 hours, with an average of 3.29 hours. The urinary concentration during the first 6 hours was 36.5 micrograms/ml in 1 patient showing the low serum level, and the first 6-hour urinary recovery rate was 7.3%. In the other 2 patients, urinary concentrations and recovery rates up to 6 hours were 87 and 62 micrograms/ml, and 17.0 and 15.1%, respectively. The second 6-hour urinary concentrations and recovery rates were 35.5 and 20.8 micrograms/ml, and 12.7 and 8.8%, respectively. The urinary recovery rates up to 12 hours were 29.7 and 23.9%, respectively. CFIX was given orally to 19 children with 20 diseases in daily doses of 6.4-12.9 mg/kg in 2 or 3 divided portions for 3 to 12 days. Clinical evaluations were made on 18 diseases. Clinical effects of CFIX were excellent in 4, good in 7 and poor in 1 of the 12 patients with tonsillitis, and excellent in 5 and good in 1 of the 6 patients with UTI. The overall clinical effectiveness rate was 94.4%. No side effects were observed in any of the 19 patients. Hematological tests, showed slight elevation of blood platelet counts in 2 patients.(ABSTRACT TRUNCATED AT 250 WORDS)